Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus.

Swanstrom AE, Haggarty B, Jordan AP, Romano J, Leslie GJ, Aye PP, Marx PA, Lackner AA, Del Prete GQ, Robinson JE, Betts MR, Montefiori DC, LaBranche CC, Hoxie JA.

J Virol. 2016 Apr 29;90(10):4966-80. doi: 10.1128/JVI.02851-15. Print 2016 May 15.

2.

Host species barriers to Jaagsiekte sheep retrovirus replication and carcinogenesis.

Caporale M, Martineau H, De las Heras M, Murgia C, Huang R, Centorame P, Di Francesco G, Di Gialleonardo L, Spencer TE, Griffiths DJ, Palmarini M.

J Virol. 2013 Oct;87(19):10752-62. doi: 10.1128/JVI.01472-13. Epub 2013 Jul 31.

3.

CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.

Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG.

J Virol. 2013 Sep;87(17):9719-32. doi: 10.1128/JVI.01254-13. Epub 2013 Jul 3.

4.

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

De Feo CJ, Weiss CD.

Viruses. 2012 Dec;4(12):3859-911. Review.

5.

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.

Lu L, Pan C, Li Y, Lu H, He W, Jiang S.

Retrovirology. 2012 Dec 7;9:104. doi: 10.1186/1742-4690-9-104.

6.

Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

de Silva TI, Aasa-Chapman M, Cotten M, Hué S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R.

J Virol. 2012 Jan;86(2):930-46. doi: 10.1128/JVI.06126-11. Epub 2011 Nov 9.

7.

Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

Vozzolo L, Loh B, Gane PJ, Tribak M, Zhou L, Anderson I, Nyakatura E, Jenner RG, Selwood D, Fassati A.

J Biol Chem. 2010 Dec 10;285(50):39314-28. doi: 10.1074/jbc.M110.155275. Epub 2010 Oct 11.

8.

Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability.

Li Q, Ali MA, Wang K, Sayre D, Hamel FG, Fischer ER, Bennett RG, Cohen JI.

PLoS One. 2010 Jun 25;5(6):e11327. doi: 10.1371/journal.pone.0011327.

9.

Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides.

Loh B, Vozzolo L, Mok BJ, Lee CC, Fitzmaurice RJ, Caddick S, Fassati A.

Chem Biol Drug Des. 2010 May;75(5):461-74. doi: 10.1111/j.1747-0285.2010.00956.x.

10.

Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain.

Kassa A, Madani N, Schön A, Haim H, Finzi A, Xiang SH, Wang L, Princiotto A, Pancera M, Courter J, Smith AB 3rd, Freire E, Kwong PD, Sodroski J.

J Virol. 2009 Sep;83(17):8364-78. doi: 10.1128/JVI.00594-09. Epub 2009 Jun 17.

11.

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.

Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, McGee-Estrada K, Mefford M, Gabuzda D, Smith AB 3rd, Sodroski J.

PLoS Pathog. 2009 Apr;5(4):e1000360. doi: 10.1371/journal.ppat.1000360. Epub 2009 Apr 3.

12.

Neutralization of HIV-1 by redirection of natural antibodies.

Perdomo MF, Levi M, Sällberg M, Vahlne A.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12515-20. doi: 10.1073/pnas.0805777105. Epub 2008 Aug 21.

13.

Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.

Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, Johnson RP, Villinger F, von Laer D, Schmitz JE.

Gene Ther. 2008 Sep;15(17):1210-22. doi: 10.1038/gt.2008.73. Epub 2008 May 1.

14.

CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates.

Laurén A, Vincic E, Hoshino H, Thorstensson R, Fenyö EM.

Retrovirology. 2007 Jul 23;4:50.

15.

Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis.

Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, Luzuriaga K, Bell J, Simmonds P, Ball J, Clapham PR.

J Virol. 2006 Jul;80(13):6324-32.

16.

Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D.

Kwon H, Bai Q, Baek HJ, Felmet K, Burton EA, Goins WF, Cohen JB, Glorioso JC.

J Virol. 2006 Jan;80(1):138-48.

17.
18.

Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry.

Daecke J, Fackler OT, Dittmar MT, Kräusslich HG.

J Virol. 2005 Feb;79(3):1581-94.

19.

Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.

Young KR, Teal BE, Brooks Y, Green TD, Bower JF, Ross TM.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1259-68.

Supplemental Content

Support Center